WNK-IN-11-d<sub>3</sub>|cas:2123483-49-6|西域试剂

WNK-IN-11-d₃,99.84%

产品编号：Bellancom-112094S| CAS NO：2123483-49-6| 分子式：C₂₁H₁₈D₃Cl₂N₅OS| 分子量：465.41

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-112094S		￥7500.00	杭州北京（现货）
Bellancom-112094S		￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

WNK-IN-11-d₃

产品介绍

WNK-IN-11-d₃ 是一种具有口服活性、选择性和强效的 With-No-Lysine (WNK) 激酶抑制剂。WNK-IN-11-d₃ 有效调节心血管稳态。

生物活性

WNK-IN-11-d₃ is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d₃ is effective at regulating cardiovascular homeostasis.

体外研究

体内研究

WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.
WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice.
WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.
WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague−Dawley rats
Dosage:	1.5 mg/kg
Administration:	P.o.
Result:	Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.

Animal Model:	FVB mice
Dosage:	30 mg/kg
Administration:	P.o.
Result:	Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.

Animal Model:	FVB mice
Dosage:	0~100 mg/kg
Administration:	P.o.
Result:	Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague−Dawley rats
Dosage:	1.5 mg/kg
Administration:	P.o.
Result:	Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.

Animal Model:	FVB mice
Dosage:	30 mg/kg
Administration:	P.o.
Result:	Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.

Animal Model:	FVB mice
Dosage:	0~100 mg/kg
Administration:	P.o.
Result:	Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (214.86 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1486 mL	10.7432 mL	21.4864 mL
5 mM	0.4297 mL	2.1486 mL	4.2973 mL
10 mM	0.2149 mL	1.0743 mL	2.1486 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式